Ephedrine Sulfate in 0.9% Sodium Chloride Injection 50 mg/10 mL
Unit of Sale NDC 14789-0250-10
Order directly through your wholesaler or from Customer Service at (888) 806-4606
Unit of sale NDC 14789-0250-10
Size: 10 mL vials
Unit of sale: 10 vials per carton
For questions, please contact customer service at 888‑806‑4606.
The Nexus Difference
Committed to Quality — From Molecules to Medicine
Starting with the source
- After years of research & development, EMERPHED completed a rigorous FDA approval process
- Consumers and health professionals rely on the drug approval process for verification of safety, effectiveness, and quality1
Partnering with the right CMO*
- Based in North America and Europe—highly regulated markets with strong compliance histories
*Contract Manufacturing Organization
Applying extra quality assurance
- EMERPHED is terminally sterilized which means the product is sterilized in its final container, ensuring a high level of sterility assurance, aligning with FDA guidelines and cGMP2
- Testing does not occur just once—every single batch goes through rigorous testing before making it to the pharmacy shelf
Delivering when others fall short
- No supply disruption vs. 203 generic injectable shortages with other suppliers3
What important safety information should I know?
WARNINGS AND PRECAUTIONS
EMERPHED can cause pressor effects with concomitant use with oxytocic drugs. Can also cause tachyphylaxis with repeated administration of ephedrine.
Most common adverse reactions during treatment: nausea, vomiting, and tachycardia.
Interactions that Augment Pressor Effect: clonidine, oxytocin and oxytocic drugs, propofol, monoamine oxidase inhibitors (MAOIs), and atropine. Monitor blood pressure.
Interactions that Antagonize the Pressor Effect: Antagonistic effects with α-adrenergic antagonists, β-adrenergic antagonists, reserpine, quinidine, mephentermine. Monitor blood pressure.
Guanethidine: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. Monitor blood pressure and adjust the dosage of pressor accordingly.
Rocuronium: Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction. Be aware of this potential interaction. No treatment or other interventions are needed.
Epidural anesthesia: Ephedrine may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia. Monitor and treat the patient according to clinical practice.
Theophylline: Concomitant use of ephedrine may increase the frequency of nausea, nervousness, and insomnia. Monitor patient for worsening symptoms and manage symptoms according to clinical practice.
Cardiac glycosides: Giving ephedrine with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias. Carefully monitor patients on cardiac glycosides who are also administered ephedrine.
Overdose of EMERPHED can cause a rapid rise in blood pressure. In the case of an overdose, careful monitoring of blood pressure is recommended. If blood pressure continues to rise to an unacceptable level, parenteral antihypertensive agents can be administered at the discretion of the clinician.
INDICATIONS AND USAGE
Ephedrine Sulfate injection is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.